Thomson Medical Group Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Thomson Medical Group wird ein jährliches Gewinn- und Umsatzwachstum von 14.4% bzw. 6.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 14% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 4.2% betragen.

Wichtige Informationen

14.4%

Wachstumsrate der Gewinne

14.0%

EPS-Wachstumsrate

Healthcare Gewinnwachstum19.0%
Wachstumsrate der Einnahmen6.7%
Zukünftige Eigenkapitalrendite4.2%
Analystenabdeckung

Low

Zuletzt aktualisiert24 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Earnings Troubles May Signal Larger Issues for Thomson Medical Group (SGX:A50) Shareholders

Sep 02
Earnings Troubles May Signal Larger Issues for Thomson Medical Group (SGX:A50) Shareholders

Calculating The Fair Value Of Thomson Medical Group Limited (SGX:A50)

Apr 01
Calculating The Fair Value Of Thomson Medical Group Limited (SGX:A50)

Should You Think About Buying Thomson Medical Group Limited (SGX:A50) Now?

Dec 16
Should You Think About Buying Thomson Medical Group Limited (SGX:A50) Now?

Here's Why Thomson Medical Group (SGX:A50) Has A Meaningful Debt Burden

Aug 31
Here's Why Thomson Medical Group (SGX:A50) Has A Meaningful Debt Burden

We Ran A Stock Scan For Earnings Growth And Thomson Medical Group (SGX:A50) Passed With Ease

Apr 24
We Ran A Stock Scan For Earnings Growth And Thomson Medical Group (SGX:A50) Passed With Ease

Thomson Medical Group (SGX:A50) Has A Pretty Healthy Balance Sheet

Mar 27
Thomson Medical Group (SGX:A50) Has A Pretty Healthy Balance Sheet

Thomson Medical Group (SGX:A50) Has A Pretty Healthy Balance Sheet

Nov 22
Thomson Medical Group (SGX:A50) Has A Pretty Healthy Balance Sheet

Should You Be Adding Thomson Medical Group (SGX:A50) To Your Watchlist Today?

Sep 30
Should You Be Adding Thomson Medical Group (SGX:A50) To Your Watchlist Today?

Market Participants Recognise Thomson Medical Group Limited's (SGX:A50) Earnings

Sep 03
Market Participants Recognise Thomson Medical Group Limited's (SGX:A50) Earnings

These 4 Measures Indicate That Thomson Medical Group (SGX:A50) Is Using Debt Reasonably Well

Feb 26
These 4 Measures Indicate That Thomson Medical Group (SGX:A50) Is Using Debt Reasonably Well

We Think Thomson Medical Group (SGX:A50) Can Stay On Top Of Its Debt

Oct 21
We Think Thomson Medical Group (SGX:A50) Can Stay On Top Of Its Debt

We Think Thomson Medical Group (SGX:A50) Has A Fair Chunk Of Debt

Mar 27
We Think Thomson Medical Group (SGX:A50) Has A Fair Chunk Of Debt

Eng Lim Just Bought A Sprinkling of Shares In Thomson Medical Group Limited (SGX:A50)

Feb 20
Eng Lim Just Bought A Sprinkling of Shares In Thomson Medical Group Limited (SGX:A50)

Should You Take Comfort From Insider Transactions At Thomson Medical Group Limited (SGX:A50)?

Jan 27
Should You Take Comfort From Insider Transactions At Thomson Medical Group Limited (SGX:A50)?

Reflecting on Thomson Medical Group's (SGX:A50) Share Price Returns Over The Last Year

Dec 23
Reflecting on Thomson Medical Group's (SGX:A50) Share Price Returns Over The Last Year

Is Thomson Medical Group (SGX:A50) Using Too Much Debt?

Nov 27
Is Thomson Medical Group (SGX:A50) Using Too Much Debt?

Gewinn- und Umsatzwachstumsprognosen

SGX:A50 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SGD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
6/30/2027443231071271
6/30/2026429201011261
6/30/202541516851151
6/30/2024356155383N/A
3/31/202435116104128N/A
12/31/202334516155173N/A
9/30/202335326115131N/A
6/30/2023361377689N/A
3/31/20233705083102N/A
12/31/20223796491115N/A
9/30/20223595978104N/A
6/30/2022339546593N/A
3/31/2022304364875N/A
12/31/2021269193058N/A
9/30/2021255162760N/A
6/30/2021240142461N/A
3/31/2021228-381453N/A
12/31/2020215-89545N/A
9/30/2020215-94250N/A
6/30/2020216-99-255N/A
12/31/201923011168N/A
9/30/201922722362N/A
6/30/201922271749N/A
3/31/201921891948N/A
12/31/2018216111641N/A
9/30/2018212101444N/A
6/30/2018208142351N/A
3/31/201820415N/A47N/A
12/31/201720116N/A52N/A
8/31/201719933N/A49N/A
8/31/201619327N/A44N/A
8/31/201517725N/A41N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: A50Das prognostizierte Gewinnwachstum (14.4% pro Jahr) liegt über der Sparquote (2.2%).

Ertrag vs. Markt: A50Die Erträge des Unternehmens (14.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt SG (10.5% pro Jahr).

Hohe Wachstumserträge: A50Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: A50Die Einnahmen des Unternehmens (6.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt SG (3.7% pro Jahr).

Hohe Wachstumseinnahmen: A50Die Einnahmen des Unternehmens (6.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: A50Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (4.2%).


Wachstumsunternehmen entdecken